1LXL | A:90-188 | NMR STRUCTURE OF BCL-XL, AN INHIBITOR OF PROGRAMMED CELL DEATH, MINIMIZED AVERAGE STRUCTURE |
1MAZ | A:90-188 | X-RAY STRUCTURE OF BCL-XL, AN INHIBITOR OF PROGRAMMED CELL DEATH |
1R2D | A:90-188 | STRUCTURE OF HUMAN BCL-XL AT 1.95 ANGSTROMS |
1R2E | A:90-188 | HUMAN BCL-XL CONTAINING A GLU TO LEU MUTATION AT POSITION 92 |
1R2G | A:90-188 | HUMAN BCL-XL CONTAINING A PHE TO TRP MUTATION AT POSITION 97 |
1R2H | A:90-188 | HUMAN BCL-XL CONTAINING AN ALA TO LEU MUTATION AT POSITION 142 |
1R2I | A:90-188 | HUMAN BCL-XL CONTAINING A PHE TO LEU MUTATION AT POSITION 146 |
1YSG | A:94-192 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-XL IN COMPLEX WITH "SAR BY NMR" LIGANDS |
1YSI | A:94-192 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-XL IN COMPLEX WITH AN ACYL-SULFONAMIDE-BASED LIGAND |
1YSN | A:94-192 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-XL COMPLEXED WITH AN ACYL-SULFONAMIDE-BASED LIGAND |
2O1Y | A:94-192 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-XL IN COMPLEX WITH AN ACYL-SULFONAMIDE-BASED LIGAND |
2O2M | A:94-192 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-XL IN COMPLEX WITH AN ACYL-SULFONAMIDE-BASED LIGAND |
2O2N | A:94-192 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-XL IN COMPLEX WITH AN ACYL-SULFONAMIDE-BASED LIGAND |
2P1L | G:90-188; G:90-188; G:90-188; G:90-188 | STRUCTURE OF THE BCL-XL:BECLIN 1 COMPLEX |
2PON | B:106-204 | SOLUTION STRUCTURE OF THE BCL-XL/BECLIN-1 COMPLEX |
2YXJ | B:90-188; B:90-188 | CRYSTAL STRUCTURE OF BCL-XL IN COMPLEX WITH ABT-737 |
3PL7 | B:90-188; B:90-188; C:63-79 | CRYSTAL STRUCTURE OF BCL-XL IN COMPLEX WITH THE BAXBH3 DOMAIN |
3QKD | B:90-188; B:90-188 | CRYSTAL STRUCTURE OF BCL-XL IN COMPLEX WITH A QUINAZOLINE SULFONAMIDE INHIBITOR |
3R85 | D:90-188; D:90-188; D:90-188; D:90-188 | CRYSTAL STRUCTURE OF HUMAN SOUL BH3 DOMAIN IN COMPLEX WITH BCL-XL |
1MK3 | A:45-143 | SOLUTION STRUCTURE OF HUMAN BCL-W PROTEIN |
1ZY3 | A:45-143 | STRUCTURAL MODEL OF COMPLEX OF BCL-W PROTEIN WITH BID BH3-PEPTIDE |
2VM6 | A:37-140 | HUMAN BCL2-A1 IN COMPLEX WITH BIM-BH3 PEPTIDE |
3MQP | A:37-140 | CRYSTAL STRUCTURE OF HUMAN BFL-1 IN COMPLEX WITH NOXA BH3 PEPTIDE, NORTHEAST STRUCTURAL GENOMICS CONSORTIUM TARGET HR2930 |
2JBY | B:78-92 | A VIRAL PROTEIN UNEXPECTEDLY MIMICS THE STRUCTURE AND FUNCTION OF PRO-SURVIVAL BCL-2 |
2JCN | A:78-177 | THE CRYSTAL STRUCTURE OF BAK1 - A MITOCHONDRIAL APOPTOSIS REGULATOR |
2XPX | B:78-91 | CRYSTAL STRUCTURE OF BHRF1:BAK BH3 COMPLEX |
2YV6 | A:78-177 | CRYSTAL STRUCTURE OF HUMAN BCL-2 FAMILY PROTEIN BAK |
3QBR | Y:12-26; Y:12-26 | BAKBH3 IN COMPLEX WITH SJA |
2K7W | A:63-158 | BAX ACTIVATION IS INITIATED AT A NOVEL INTERACTION SITE |
3PK1 | D:63-80; D:63-80; C:213-312; C:213-312 | CRYSTAL STRUCTURE OF MCL-1 IN COMPLEX WITH THE BAXBH3 DOMAIN |
1YSW | A:94-192 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-2 COMPLEXED WITH AN ACYL-SULFONAMIDE-BASED LIGAND |
2O21 | A:94-192 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-2 IN COMPLEX WITH AN ACYL-SULFONAMIDE-BASED LIGAND |
2O22 | A:94-192 | SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-2 IN COMPLEX WITH AN ACYL-SULFONAMIDE-BASED LIGAND |
2W3L | B:56-154; B:56-154 | CRYSTAL STRUCTURE OF CHIMAERIC BCL2-XL AND PHENYL TETRAHYDROISOQUINOLINE AMIDE COMPLEX |
2XA0 | B:97-195; B:97-195 | CRYSTAL STRUCTURE OF BCL-2 IN COMPLEX WITH A BAX BH3 PEPTIDE |
2KBW | A:213-312 | SOLUTION STRUCTURE OF HUMAN MCL-1 COMPLEXED WITH HUMAN BID_BH3 PEPTIDE |
2NL9 | A:213-312 | CRYSTAL STRUCTURE OF THE MCL-1:BIM BH3 COMPLEX |
2NLA | A:213-312 | CRYSTAL STRUCTURE OF THE MCL-1:MNOXAB BH3 COMPLEX |
2PQK | A:213-312 | X-RAY CRYSTAL STRUCTURE OF HUMAN MCL-1 IN COMPLEX WITH BIM BH3 |
3KJ0 | A:213-312 | MCL-1 IN COMPLEX WITH BIM BH3 MUTANT I2DY |
3KJ1 | A:213-312 | MCL-1 IN COMPLEX WITH BIM BH3 MUTANT I2DA |
3KJ2 | A:213-312 | MCL-1 IN COMPLEX WITH BIM BH3 MUTANT F4AE |
3KZ0 | B:213-312; B:213-312 | MCL-1 COMPLEX WITH MCL-1-SPECIFIC SELECTED PEPTIDE |
3MK8 | B:9-23; B:9-23 | THE MCL-1 BH3 HELIX IS AN EXCLUSIVE MCL-1 INHIBITOR AND APOPTOSIS SENSITIZER |